| Source publication date | (updated May 2026) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Telehealth FX |
| URL | telehealthfx.pages.dev/blog/enclomiphene-vs-trt-2026 (opens in a new tab) |
Specific Claim Evaluated
Enclomiphene is the fertility-preserving alternative to testosterone therapy and can boost testosterone without sacrificing fertility.
Primary Research Supporting or Contradicting the Claim
Evidence for fertility-related effects comes from small, short trials showing maintained sperm concentration, such as an open-label phase IIb study in 12 men (Kaminetsky et al., 2013). Guidelines advise against testosterone in men planning fertility (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
Enclomiphene has been shown to maintain sperm concentration over months in small trials of men with secondary hypogonadism. It has not been shown to preserve fertility as measured by conception, it is not FDA approved, and it is ineffective in primary hypogonadism.
Rationale for Grade
The page presents a surrogate laboratory finding as a guarantee of fertility in its title and calls to action. It does not state the regulatory status prominently or the limitation to secondary hypogonadism. The commercial framing turns preliminary evidence into a definitive clinical promise.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs" - Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PMID
Supporting excerpt: "phase IIB study in 12 men with secondary hypogonadism"